Compare Diageo plc (DEO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Twist Bioscience Corp — how do they compare? Diageo plc trades at $93.76 (market cap $53.75B), while Twist Bioscience Corp trades at $123.13 (market cap $7.82B). The key difference: Diageo plc is far larger — about 6.9× Twist Bioscience Corp's market cap, and Diageo plc pays a 3.42% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| DEO | TWST | |
|---|---|---|
Market Cap | $53.75B | $7.82B |
Sector | Technology | Health |
52-Week High | $115.33 | $124.88 |
52-Week Low | $72.47 | $24.16 |
Enterprise Value | $73.25B | $7.75B |
Dividend Yield | 3.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $96.35, up 3.83% with bullish technical signals from moving averages. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. Analyst consensus leans positive with 48.65% buy ratings, though valuation metrics appear elevated with a P/E of 31.16. Recent news highlights a $1 billion cost-cutting plan and strategic focus on spirits and Guinness to drive turnaround.
The outlook is cautiously optimistic with management's restructuring program expected to improve margins and cash flow. Key risks include ongoing weakness in North American markets and competitive pressures. Wall Street sees potential upside with recent target increases, but investors should monitor execution of the turnaround plan amid challenging market conditions.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
